Eton Pharmaceuticals Inc (ETON)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
ETON
Eton Pharmaceuticals Inc
$55.62
+0.47%
HEALTHCARE · Cap: $1.65B
TAK
Takeda Pharmaceutical Co Ltd ADR
$17.86
0.00%
HEALTHCARE · Cap: $58.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 4374098% more annual revenue ($4.62T vs $105.59M). ETON leads profitability with a 12.0% profit margin vs -3.5%. TAK earns a higher WallStSmart Score of 53/100 (C-).
ETON
Buy52
out of 100
Grade: C-
TAK
Buy53
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.8%
Revenue surging 98.6% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Generating 73.8B in free cash flow
Large-cap with strong market position
Areas to Watch
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Trading at 33.7x book value
ROE of -4.8% — below average capital efficiency
ROE of 2.4% — below average capital efficiency
Earnings declined 9.8%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ETON
The strongest argument for ETON centers on Operating Margin, Revenue Growth. Revenue growth of 98.6% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.42 suggests the stock is reasonably priced for its growth.
Bear Case : ETON
The primary concerns for ETON are Market Cap, P/E Ratio, Price/Book. A P/E of 147.9x leaves little room for execution misses.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ETON profiles as a growth stock while TAK is a turnaround play — different risk/reward profiles.
ETON carries more volatility with a beta of 0.90 — expect wider price swings.
ETON is growing revenue faster at 98.6% — sustainability is the question.
TAK generates stronger free cash flow (73.8B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (53/100 vs 52/100) and 10.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eton Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?